)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nephros
Nephros (NEPH) investor relations material
Nephros Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue rose 18% YoY to $5.622M; net income was $512K and Adjusted EBITDA was ~$0.6M.
9M revenue increased 20% to $16.851M; net income was $1.849M and Adjusted EBITDA was $2.045M.
Trailing 12-month revenue exceeded $21M, and active customer sites reached a record 1,766.
Financial highlights
Q3 product revenue was $5.43M vs. $4.60M; service, royalty and other revenue was $191K vs. $168K.
9M product revenue was $16.17M vs. $13.61M; service, royalty and other revenue was $679K vs. $447K.
Q3 operating income was $501K vs. $314K; net income was $512K vs. $337K.
Q3 SG&A rose 9% to $2.43M and R&D declined 2% to $331K; 9M SG&A rose 10% to $7.36M and R&D to $1.04M.
Outlook and guidance
Q4 priorities: execute, finish 2026 strong, grow programmatic and service revenue, expand the installed base, improve margins, and strengthen education and product capabilities.
Management plans continued investment in products, services, marketing, sales and working capital; existing cash and projected operating cash flows are expected to fund the operating plan for at least 12 months from financial-statement issuance.
Inventory purchases are expected to moderate as stock sells through; collections and inventory management are expected to support improved working capital and operating cash flow.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nephros
- Two director seats, auditor ratification, executive pay, and annual say-on-pay cadence go to a vote.NEPH
Proxy filing - Record Q2 2026 revenue and net income growth, driven by recurring and service revenues, aided by a tariff refund.NEPHQ2 2026
- Q1 revenue up 7% to $5.2M; recurring sales and service drive growth, margin recovery expected.NEPHInvestor update
- Advanced filtration solutions, recurring revenue, and digital innovation drive profitable growth.NEPHCorporate presentation
- Q1 2026 revenue hit $5.2M, but margin fell to 57% amid tariff and cost pressures.NEPHQ1 2026
- Profitable, debt-free filtration leader expanding with digital tools and nano/microplastic removal.NEPHCorporate presentation
- Record 33% revenue growth, $1.2M net income, and strong cash, despite margin pressure from tariffs.NEPHQ4 2025
- Q2 2025 revenue up 36% with record margins, profitability, and expanding customer base.NEPHQ2 2025
- Q2 2024 revenue fell 8% to $3.3M, but programmatic sales and net loss improved year-over-year.NEPHQ2 2024
Next Nephros earnings date
Q4 202611 Mar, 2027
Nephros
Next Nephros earnings date
Q4 202611 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nephros Inc. is a medical technology company specializing in water filtration systems and medical devices. The company designs and manufactures filtration products that target microbial contaminants in water used for dialysis and other medical applications. Nephros serves healthcare facilities, dialysis centers, and commercial industries by providing solutions that improve water quality and reduce infection risks. The company’s filtration systems are also used in various industrial and commercial settings to ensure clean and safe water supply. The company is headquartered in South Orange, New Jersey, and its shares are listed on the NASDAQ.